- Report
- February 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1140EUR$1,250USD£975GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
Dobutamine is a cardiovascular drug used to treat heart failure and other cardiac conditions. It is a synthetic catecholamine that acts as a positive inotropic agent, meaning it increases the force of contraction of the heart muscle. It is administered intravenously and is used to treat low cardiac output states, such as those caused by myocardial infarction, cardiomyopathy, and septic shock. It is also used to treat hypotension and bradycardia. Dobutamine is often used in combination with other drugs, such as diuretics, to treat heart failure.
The Dobutamine market is highly competitive, with a number of companies offering products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies include Bristol-Myers Squibb, AstraZeneca, and Teva Pharmaceuticals. Show Less Read more